Accretion Nutraveda
ACCRETIONNUTRAVEDALTD NSE
Accretion Nutraveda
HealthcareNSE: ACCRETIONNUTRAVEDALTD BSE: 544694 Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹204 Cr
Volatility
Low Risk
P/E Ratio
0
EBITDA
₹7.00 Cr
Return on Equity
14.29%
Debt to Equity
0.12
Book Value
₹49
52W High
₹313
52W Low
₹150.1
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.3 to 88.1 days.
- Working capital days have increased from 111 days to 196 days
Growth Rate
Revenue Growth
111% lower than
3Y
Net Income Growth
104% lower than
3Y
Cash Flow Change
-324%
ROE
-71.13% lower than
3Y
ROCE
-63.21% higher than
3Y
EBITDA Margin (Avg.)
-10.82% higher than
3Y
Quarterly Results
| Particulars | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 10.85 | 14.06 | 19.54 |
| Expenses | 8.27 | 10.76 | 15.98 |
| Operating Profit | 2.58 | 3.3 | 3.56 |
| OPM % | 23.78% | 23.47% | 18.22% |
| Other Income | 0 | 0 | 0.11 |
| Interest | 0.26 | 0.26 | 0.27 |
| Depreciation | 0.11 | 0.17 | 0.1 |
| PBT | 2.21 | 2.87 | 3.3 |
| Tax % | 22.17% | 18.47% | 18.48% |
| Net Profit | 1.72 | 2.33 | 2.69 |
| EPS in Rs | 35.32 | 4.38 | 3.72 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 2.89 | 5.01 | 16 | 33.59 |
| Expenses | 2.27 | 3.78 | 12.29 | 26.7 |
| Operating Profit | 0.62 | 1.23 | 3.71 | 6.89 |
| OPM % | 21.45% | 24.55% | 23.19% | 20.51% |
| Other Income | 0.17 | 0.19 | 0.01 | 0.11 |
| Interest | 0.19 | 0.24 | 0.35 | 0.53 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.26 |
| PBT | 0.29 | 0.92 | 3.15 | 6.21 |
| Tax % | 3.45% | 9.78% | 20.63% | 18.36% |
| Net Profit | 0.28 | 0.82 | 2.5 | 5.07 |
| EPS in Rs | 7.78 | 22.78 | 51.33 | 7 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 0.36 | 0.36 | 0.49 | 7.24 |
| Reserves | -0.1 | 0.72 | 4.56 | 28.23 |
| Borrowings | 1.97 | 2.17 | 3.86 | 4.23 |
| Other Liabilities | 1.83 | 1.39 | 1.63 | 2.08 |
| Total Liabilities | 4.06 | 4.64 | 10.54 | 41.78 |
| Fixed Assets | 1.49 | 1.28 | 1.83 | 1.66 |
| CWIP | 0 | 0.1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 2.57 | 3.26 | 8.71 | 40.12 |
| Total Assets | 4.06 | 4.64 | 10.54 | 41.78 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 0.68 | 0.23 | -2.22 | -9.42 |
| Investing | -0.01 | -0.16 | -0.87 | -14.5 |
| Financing | -0.63 | -0.04 | 2.98 | 25.19 |
| Net Cash Flow | 0.04 | 0.03 | -0.1 | 1.26 |
| Free Cash Flow | 0.67 | 0.07 | -3.09 | -15.45 |
| CFO/OP | 110 | 27 | -42 | -113 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 101 | 18.21 | 74.6 | 88.13 |
| Inventory Days | 279 | 304 | 159 | 136 |
| Days Payable | 354 | 114 | 30.73 | 11.35 |
| Cash Conversion Cycle | 25.89 | 208 | 202 | 213 |
| Working Capital Days | 8.84 | 7.29 | 129 | 196 |
| ROCE % | — | 42.34% | 57.57% | 27.73% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Accretion Nutraveda insights
29 extracted metrics + investor summaries across FY23–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Resignation of Director
8 May - FY26 audited results approved; two independent directors resigned, two new independent directors appointed, auditors reappointed. 8 May - FY26 audited results approved; two independent directors resigned, two new independent directors appointed, auditors reappointed.
2
Announcement under Regulation 30 (LODR)-Change in Management
8 May - Board approved FY26 audited results; two independent directors resigned, and two new independent directors appointed on 8 May 2026. 8 May - Board approved FY26 audited results; two independent directors resigned, and two new independent directors appointed on 8 May 2026.
3
Announcement under Regulation 30 (LODR)-Change in Management
8 May - Audited FY26 profit rose to ₹506.83 lakh; two independent directors resigned, two appointed. 8 May - Audited FY26 profit rose to ₹506.83 lakh; two independent directors resigned, two appointed.
4
Appointment Of Secretarial Auditors
8 May - FY26 audited results approved; two independent directors resigned, two new independent directors appointed on 8 May 2026. 8 May - FY26 audited results approved; two independent directors resigned, two new independent directors appointed on 8 May 2026.
5
Appointment Of Internal Auditors
8 May - FY26 audited results approved; two independent directors resigned and two appointed on 8 May 2026. 8 May - FY26 audited results approved; two independent directors resigned and two appointed on 8 May 2026.
4
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association 1 Sept 2026
General_Announcements
Frequently Asked Questions about Accretion Nutraveda
What does Accretion Nutraveda Ltd do?
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.[1]
Where is Accretion Nutraveda Ltd (544694) listed?
Accretion Nutraveda Ltd trades as ACCRETIONNUTRAVEDALTD on the NSE and under code 544694 on the BSE.
Which sector does Accretion Nutraveda Ltd belong to?
Accretion Nutraveda Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Accretion Nutraveda Ltd?
Accretion Nutraveda Ltd has a market capitalisation of ₹204.2 Cr, which places it in the Small Cap band.
What is the PE ratio of Accretion Nutraveda Ltd?
Accretion Nutraveda Ltd trades at a PE ratio of 0.00, against a book value of ₹49 per share.
What is the 52-week high and low of Accretion Nutraveda Ltd?
Over the last 52 weeks Accretion Nutraveda Ltd has traded between ₹150.1 and ₹313.
What is the Return on Equity (ROE) of Accretion Nutraveda Ltd?
Accretion Nutraveda Ltd reported a return on equity of 14.29%. Its debt-to-equity ratio is 0.12.
Company Information
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544694.md for Accretion Nutraveda Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.